Company intelligence / Profile preview

Courage Center

Newton, Massachusetts, United Statescouragecentersc.org ↗

Ownership: Private
Development stage: Other

Overview

Courage Therapeutics is developing novel peptides and small molecules targeting GPCRs involved in energy homeostasis. Their lead programs are preclinical candidates with potent MC4R agonist activity for obesity and MC3R antagonist/agonist activity for anorexia nervosa and binge eating disorder. The company has not yet entered clinical trials but has established a strong IP position through licensing from the University of Michigan and ongoing medicinal chemistry efforts led by Dr. Tomi Sawyer.

Therapeutic areas: PsychiatryEndocrinology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

University of Michigan (licensing agreement on intellectual property related to melanocortin receptors)Arsenal Bridge Ventures (lead investor/funding partner)

Beyond the preview

Go deeper on Courage Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Courage Center.

Explore the full profile